Curie.Bio

As the newest addition to our CSO Partner Team, Philippe Delerive has advanced multiple therapies to the clinic in areas including #cardiovascular, #metabolic, and #inflammatory diseases. To get there, he says, “I have consistently sought out opportunities to make a significant impact for patients.” “My decision to join Curie.Bio was driven by the prospect of collaborating with world-class drug hunters and visionary company builders, all working towards the shared goal of creating novel therapeutic companies that address unmet medical needs.” He shares more on our website. https://lnkd.in/g_6yb89P

Curie.Bio Co-founder and CEO Zach Weinberg has been named to Business Insider's Seed 100 list, recognizing investors who provide essential early support to help #startups succeed. Zach’s perspective as a serial founder with several successful exits uniquely positions him to identify and empower biotech entrepreneurs, having experienced firsthand the challenges founders face. At Curie.Bio, we've created a team of experienced company builders like Zach to play a key role in founders' journeys to discovering and developing important new medicines. Check out the full list here. https://lnkd.in/gdXuCSMr

If you’ve pitched your idea to us, you’ve likely met Thomas Horn. In his role as Investment Diligence & Operations Lead, Thomas interfaces between founders and our world-class team of scientists and drug hunters, ensuring every founder gets meaningful feedback in a timely manner. Thomas helps guide founders through our early diligence process backed by a foundation of experience in drug discovery, from early stage to approved products. https://lnkd.in/e2KCWRYn

Christophe Muller, our Chief of External R&D and Partnering, is an organic chemist by training — but at his core, he’s a builder. Over his 25-year career in biotech, what’s fueled him most is the opportunity to create: molecules, teams, and trusted partnerships. At Curie.Bio, Christophe plays a central role in supporting all stakeholders across our ecosystem, always grounding decisions in one guiding principle: advancing drug discovery and development. Learn more about Christophe and his journey on our website: https://lnkd.in/erpazxJk

At Curie.Bio, our team understands firsthand the importance of having access to people with the experience and wisdom to help your idea succeed.  Headed to Chicago for #AACR25? Alexis Borisy will be sharing his decades of insight as a company creator, entrepreneur and investor on a special forum Tuesday, April 29 at 5:00pm.

You're working on a brilliant therapeutic idea, and now you're looking for a VC partner to help. What's the best way to engage? Tune in to watch Curie.Bio's George Voren discuss how founders can put their best foot forward with Curie.Bio and other VCs during the Inside Fundraising seminar with Nucleate. They will cover the following topics: 1. How to effectively get in contact with a VC (and the right person at that VC). 2. Key elements for a company to highlight in the initial engagement. 3. Common mistakes founders make when pitching. 4. Typical timeline for the diligence process. 5. Ways that founders can maintain a relationship following the initial outcome. Register for free at the link below.

CXO Darryl B. McConnell’s career in drug discovery and development has thus far spanned 24 development-stage compounds and 11 clinical-stage drug candidates. We are thrilled to have him on the Curie.Bio team to leverage that expertise and complement founders in their journey to bringing new drugs to patients. Darryl shares more about his passion for our work here. https://lnkd.in/eJVVDCKN

Biotech isn’t hard. It’s brutal. Christoph Lengauer said it clearly today—and I couldn’t agree more. Most people still think biotech is just science and luck. But here’s the reality: From 10,000 scientific ideas, maybe one becomes a product. From 100 preclinical assets, only one makes it to market. From 100 clinical programs, just 6 get approved. And most drug developers? Will never see a product reach the market. Let that sink in. And yet—this is the best time to build and invest in biotech. Yes, valuations are low. Yes, the market looks dead. Yes, people are anxious. But that’s exactly why now is the moment. This is where 10x returns start. Not when CNBC celebrates you—when no one’s looking. So what does it take? Three things. Science. Medicine. Business. You don’t need 50 people. You need 3–5 battle-tested operators who know how to: • Translate basic research into phase III-ready assets • Design programs around real medical need • Tell a corporate story to investors and a transaction story to acquirers • Manage a global CRO ecosystem—not a CapEx-heavy internal lab This is how Christoph and his team at Curie.Bio work. They don’t just talk translational science. They execute it—lean, fast, and globally networked. Oh—and they know most biotech funds don’t even return 1x. But the ones that do it right? They shoot for 2x to 10x—and hit it. Because they invest in teams, not just tech. They optimize for focus, repeatability, and capital efficiency. 95 people with a track record of bringing 37 drugs to the market and 1.2 bn dollars capital under management. Biotech isn’t for tourists. But if you want to understand it? Talk to Christoph. #Biotech #Investing #Startups #DrugDevelopment #TranslationalMedicine #VentureCapital #Strategy #Leadership #Innovation

During his drug development career, Ryan Sullivan has led or contributed to the development of several complex biologics - including antibodies, cytokines, vaccines, and cell therapies. He brings those insights to the team at Curie.Bio and works closely with our PortCo founders to design and build successful biologic therapies. "Biologics are inherently complex, and navigating the maze of their discovery and development even more so. Curie.Bio was created to streamline this journey for Founders, and being part of that mission is what inspires me every day." Learn more about how Ryan can help you design your drug here: https://lnkd.in/eCJNeRrx

Throughout Aron Jaffe’s career, he has been committed to advancing and leveraging bleeding-edge technologies to uncover new biological insights and unlock new therapeutic opportunities. At Curie.Bio, Aron helps our founders translate new biological insights and platform technologies into great therapeutics companies that can deliver life-changing medicines. Check out a few of the bleeding-edge scientific innovations led by Aron below. Notch2 is required for inflammatory cytokine-driven goblet cell metaplasia in the lung: https://lnkd.in/eAEi-bcU A single-cell atlas of the airway epithelium reveals the CFTR-rich pulmonary ionocyte: https://lnkd.in/ezjfJy5Y A potent epigenetic editor targeting human PCSK9 for durable reduction of low-density lipoprotein cholesterol levels:  https://lnkd.in/eC55NcV6